Profile of clinical trials with drugs for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Spain

DOI record: { "DOI": "10.1016/j.farma.2026.01.003", "ISSN": [ "1130-6343" ], "URL": "http://dx.doi.org/10.1016/j.farma.2026.01.003", "alternative-id": [ "S1130634326000061" ], "assertion": [ { "label": "This article is maintained by", "name": "publisher", "value": "Elsevier" }, { "label": "Article Title", "name": "articletitle", "value": "Profile of clinical trials with drugs for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Spain" }, { "label": "Journal Title", "name": "journaltitle", "value": "Farmacia Hospitalaria" }, { "label": "CrossRef DOI link to publisher maintained version", "name": "articlelink", "value": "https://doi.org/10.1016/j.farma.2026.01.003" }, { "label": "CrossRef DOI link to the associated document", "name": "associatedlink", "value": "https://doi.org/10.1016/j.farma.2025.10.017" }, { "label": "Content Type", "name": "content_type", "value": "article" }, { "label": "Copyright", "name": "copyright", "value": "© 2025 Sociedad Española de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier España, S.L.U." } ], "author": [ { "affiliation": [], "family": "Tejedor-Tejada", "given": "Eduardo", "sequence": "first" }, { "affiliation": [], "family": "González-Pérez", "given": "Cristina", "sequence": "additional" }, { "affiliation": [], "family": "Goyache Goñi", "given": "María del Puy", "sequence": "additional" }, { "affiliation": [], "family": "Suñé-Martín", "given": "María Pilar", "sequence": "additional" }, { "affiliation": [], "family": "Serrano-Alonso", "given": "María", "sequence": "additional" }, { "affiliation": [], "family": "Sánchez-del Hoyo", "given": "Rafael", "sequence": "additional" } ], "container-title": "Farmacia Hospitalaria", "container-title-short": "Farmacia Hospitalaria", "content-domain": { "crossmark-restriction": true, "domain": [ "elsevier.es", "elsevier.com", "sciencedirect.com" ] }, "created": { "date-parts": [ [ 2026, 2, 18 ] ], "date-time": "2026-02-18T21:03:21Z", "timestamp": 1771448601000 }, "deposited": { "date-parts": [ [ 2026, 2, 18 ] ], "date-time": "2026-02-18T21:03:24Z", "timestamp": 1771448604000 }, "indexed": { "date-parts": [ [ 2026, 2, 18 ] ], "date-time": "2026-02-18T22:02:50Z", "timestamp": 1771452170377, "version": "3.50.1" }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2026, 2 ] ] }, "language": "en", "license": [ { "URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2026, 2, 1 ] ], "date-time": "2026-02-01T00:00:00Z", "timestamp": 1769904000000 } }, { "URL": "https://www.elsevier.com/legal/tdmrep-license", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2026, 2, 1 ] ], "date-time": "2026-02-01T00:00:00Z", "timestamp": 1769904000000 } }, { "URL": "http://creativecommons.org/licenses/by-nc-nd/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2026, 1, 17 ] ], "date-time": "2026-01-17T00:00:00Z", "timestamp": 1768608000000 } } ], "link": [ { "URL": "https://api.elsevier.com/content/article/PII:S1130634326000061?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://api.elsevier.com/content/article/PII:S1130634326000061?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining" } ], "member": "78", "original-title": [], "prefix": "10.1016", "published": { "date-parts": [ [ 2026, 2 ] ] }, "published-print": { "date-parts": [ [ 2026, 2 ] ] }, "publisher": "Elsevier BV", "reference": [ { "author": "World Health Organisation", "key": "10.1016/j.farma.2026.01.003_bb0005" }, { "author": "World Health Organisation. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)", "key": "10.1016/j.farma.2026.01.003_bb0010" }, { "DOI": "10.4014/jmb.2003.03011", "article-title": "Myoung J., et al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19)", "author": "Ahn", "doi-asserted-by": "crossref", "first-page": "313", "issue": "3", "journal-title": "J Microbiol Biotechnol", "key": "10.1016/j.farma.2026.01.003_bb0015", "volume": "30", "year": "2020" }, { "author": "European Medicines Agency. Amsterdam: European Medicines Agency. Kaletra: EPAR – product information", "key": "10.1016/j.farma.2026.01.003_bb0020" }, { "author": "Drug Information Center of the Spanish Agency of Medicines and HealthProducts. (AEMPS - CIMA). Madrid. Dolquine: Drug data sheet. Last review 2023", "key": "10.1016/j.farma.2026.01.003_bb0025" }, { "author": "Drug Information Center of the Spanish Agency of Medicines and Health Products. (AEMPS - CIMA). Madrid. Azithromycin: Drug data sheet Last review 2003", "key": "10.1016/j.farma.2026.01.003_bb0030" }, { "key": "10.1016/j.farma.2026.01.003_bb0035", "unstructured": "Real Decreto 1090/2015, de 4 de diciembre, por el que se regulan los ensayos clínicos con medicamentos. Boletín Oficial del Estado, núm. 307, 24 de diciembre de 2015, pp. 121069–121131. [Accessed 10 Feb 2025]. Available from: https://www.boe.es/boe/dias/2015/12/24/pdfs/BOE-A-2015-14082.pdf" }, { "DOI": "10.1056/NEJMoa2023184", "article-title": "Repurposed antiviral drugs for Covid-19 - interim WHO Solidarity trial results", "author": "Pan", "doi-asserted-by": "crossref", "first-page": "497", "issue": "6", "journal-title": "N Engl J Med", "key": "10.1016/j.farma.2026.01.003_bb0040", "volume": "384", "year": "2021" }, { "DOI": "10.1056/NEJMoa2021436", "article-title": "Dexamethasone in hospitalized patients with Covid-19", "author": "Collaborative Group", "doi-asserted-by": "crossref", "first-page": "693", "issue": "8", "journal-title": "N Engl J Med", "key": "10.1016/j.farma.2026.01.003_bb0045", "volume": "384", "year": "2021" }, { "author": "España, líder europeo en investigación clínica con medicamentos. Agencia Española del Medicamento. Feb 2025", "key": "10.1016/j.farma.2026.01.003_bb0050" }, { "key": "10.1016/j.farma.2026.01.003_bb0055", "unstructured": "Castro-Balado A., Varela-Rey I., Bandín-Vilar E.J., Busto-Iglesias M., García-Quintanilla L., Mondelo-García C., et al. Clinical research in hospital pharmacy during the fight against COVID-19. Farm Hosp. 2020;44(7):66–70. English. doi:10.7399/fh.11494." }, { "author": "IQVIA. Assessing the clinical trial ecosystem in Europe", "key": "10.1016/j.farma.2026.01.003_bb0060" }, { "DOI": "10.1016/j.cct.2022.106709", "article-title": "Neumann S., et al. COVID-19 interventional trials: analysis of data sharing intentions during a time of pandemic", "author": "Larson", "doi-asserted-by": "crossref", "first-page": "106709", "journal-title": "Contemp Clin Trial", "key": "10.1016/j.farma.2026.01.003_bb0065", "volume": "115", "year": "2022" }, { "DOI": "10.1002/ddr.21762", "article-title": "Review of registered clinical trials for the treatment of COVID-19", "author": "Babaei", "doi-asserted-by": "crossref", "first-page": "474", "issue": "4", "journal-title": "Drug Dev Res", "key": "10.1016/j.farma.2026.01.003_bb0070", "volume": "82", "year": "2021" }, { "DOI": "10.1136/bmjopen-2020-039978", "article-title": "Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis", "author": "Mehta", "doi-asserted-by": "crossref", "issue": "6", "journal-title": "BMJ Open", "key": "10.1016/j.farma.2026.01.003_bb0075", "volume": "10", "year": "2020" }, { "DOI": "10.1038/s41467-021-21220-5", "article-title": "Hung A., et al. Methodological quality of COVID-19 clinical research", "author": "Jung", "doi-asserted-by": "crossref", "first-page": "943", "issue": "1", "journal-title": "Nat Commun", "key": "10.1016/j.farma.2026.01.003_bb0080", "volume": "12", "year": "2021" }, { "key": "10.1016/j.farma.2026.01.003_bb0085", "unstructured": "Johns Hopkins University Bloomberg School of Public Health. Majority of first-wave COVID-19 clinical trials have significant design short comings, study finds. Science Daily. [Accessed 20 Feb 2025]. Available from: www.sciencedaily.com/releases/2020/06/200609130006.htm" }, { "DOI": "10.1016/j.ejim.2020.07.002", "article-title": "Waste in COVID-19 clinical trials conducted in western Europe", "author": "Dal-Ré", "doi-asserted-by": "crossref", "first-page": "91", "journal-title": "Eur J Intern Med", "key": "10.1016/j.farma.2026.01.003_bb0090", "volume": "81", "year": "2020" }, { "article-title": "Hydroxychloroquine for COVID19: the curtains close on a comedy of errors", "author": "Schwartz", "journal-title": "Lancet Reg Health Am", "key": "10.1016/j.farma.2026.01.003_bb0095", "volume": "11", "year": "2022" }, { "DOI": "10.1016/j.ijantimicag.2024.107416", "doi-asserted-by": "crossref", "key": "10.1016/j.farma.2026.01.003_bb0100", "unstructured": "Gautret P., Lagier J.C., Parola P., Hoang V.T., Meddeb L., Mailhe M., et bal. Retracted: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949. Epub 2020 Mar 20. Retraction in: Int J Antimicrob Agents. 2025 Jan;65(1):107416. doi: 10.1016/j.ijantimicag.2024.107416. doi:10.1016/j.ijantimicag.2020.105949." }, { "DOI": "10.1186/s12874-023-02110-4", "article-title": "Exploring trial publication and research waste in COVID-19 randomised trials of hydroxychloroquine, corticosteroids, and vitamin D: a meta-epidemiological cohort study", "author": "Fincham", "doi-asserted-by": "crossref", "first-page": "19", "issue": "1", "journal-title": "BMC Med Res Methodol", "key": "10.1016/j.farma.2026.01.003_bb0105", "volume": "24", "year": "2024" }, { "DOI": "10.3389/fmed.2023.1198088", "article-title": "Ory M.G., et al. External control arms: COVID-19 reveals the merits of using real world evidence in real-time for clinical and public health investigations", "author": "Silva", "doi-asserted-by": "crossref", "first-page": "1198088", "journal-title": "Front Med (Lausanne)", "key": "10.1016/j.farma.2026.01.003_bb0110", "volume": "10", "year": "2023" }, { "DOI": "10.1001/jamanetworkopen.2024.20458", "article-title": "Fowler R., et al. Barriers, solutions, and opportunities for adapting critical care clinical trials in the COVID-19 pandemic", "author": "Cook", "doi-asserted-by": "crossref", "issue": "7", "journal-title": "JAMA Netw Open", "key": "10.1016/j.farma.2026.01.003_bb0115", "volume": "7", "year": "2024" }, { "DOI": "10.1002/14651858.MR000011.pub3", "doi-asserted-by": "crossref", "key": "10.1016/j.farma.2026.01.003_bb0120", "unstructured": "Showell M.G., Cole S., Clarke M.J., DeVito N.J., Farquhar C., Jordan V. Time to publication for results of clinical trials. Cochrane Database Syst Rev. 2024 Nov 27;11(11):MR000011. doi:10.1002/14651858.MR000011.pub3 ." }, { "author": "Asociación Española contra el Cáncer. Comprometidos con la investigación en cáncer", "key": "10.1016/j.farma.2026.01.003_bb0130" }, { "DOI": "10.1016/j.jbspin.2022.105427", "article-title": "COVID-19 as a source of poor publications", "author": "Maisonneuve", "doi-asserted-by": "crossref", "issue": "6", "journal-title": "Joint Bone Spine", "key": "10.1016/j.farma.2026.01.003_bb0135", "volume": "89", "year": "2022" }, { "DOI": "10.1056/NEJMoa2021436", "article-title": "Bell J.L.,et al. Dexamethasone in hospitalized patients with Covid-19", "author": "Collaborative Group", "doi-asserted-by": "crossref", "first-page": "693", "issue": "8", "journal-title": "N Engl J Med", "key": "10.1016/j.farma.2026.01.003_bb0140", "volume": "384", "year": "2021" }, { "DOI": "10.1126/science.abc1731", "article-title": "Against pandemic research exceptionalism", "author": "London", "doi-asserted-by": "crossref", "first-page": "476", "issue": "6490", "journal-title": "Science", "key": "10.1016/j.farma.2026.01.003_bb0145", "volume": "368", "year": "2020" }, { "author": "European Medicines Agency", "key": "10.1016/j.farma.2026.01.003_bb0150" }, { "author": "Júarez-Gimenez", "key": "10.1016/j.farma.2026.01.003_bb0155" }, { "author": "Agencia Española de Medicamentos y Productos Sanitarios", "key": "10.1016/j.farma.2026.01.003_bb0160" } ], "reference-count": 31, "references-count": 31, "relation": {}, "resource": { "primary": { "URL": "https://linkinghub.elsevier.com/retrieve/pii/S1130634326000061" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Profile of clinical trials with drugs for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Spain", "type": "journal-article", "update-policy": "https://doi.org/10.1016/elsevier_cm_policy" }